Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4298 in Malignant Solid Tumors
NCT07229612Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2025
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4298 in malignant solid tumor, sponsored by Suzhou Suncadia Biopharmaceutical. Started Dec 2025; status: recruiting.
02
Drugs
SHR-4298
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07229612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229612.